[7] In 2005, Umetsu joined Harvard Medical School as the Prince Turki Bin Abdul Aziz al Saud Professor of Pediatrics and conducted NIH-funded laboratory research for over two decades.
[10] He also served on the board of the American Academy of Allergy and Immunology from 2002 to 2007, as a member of the Allergenic Products Advisory Committee at CBER FDA from 1998 to 2002, and as a Study Section chair with the Center for Scientific Review from 1998 to 2000.
In 2013, Umetsu transitioned from academia to the role of Principal Medical Director in Respiratory and Allergic Diseases and Global Development Lead for Xolair at Genentech.
[11][7] Umetsu's research has shown that omalizumab, an anti-IgE monoclonal antibody, marketed as Xolair by Genentech, can significantly mitigate allergic reactions in individuals with severe food allergies.
[13] In 2004, Umetsu led a team that developed vaccines that reduced or eliminated dogs' allergic reactions to peanuts, milk, and wheat.